FDA announced on March 11, 2026 the launch of the Adverse Event Monitoring System (AEMS), a modernized database designed to centralize and streamline the analysis and publication of adverse event reports for all FDA-regulated products. This new platform, with enhanced analytics and real-time data capabilities, marks a significant shift in how adverse event data is shared by FDA and accessed and used by industry and the public.
While the launch of AEMS does not alter FDA’s requirements for submission of adverse event information (MDRs), FDA also announced on May 11, 2026, specific changes to the coding (i.e., country codes and adverse event codes that will no longer be supported) used in electronic MDR submissions as part of the consolidation of reports into AEMS. Moreover, companies operating in the affected product areas should understand AEMS’s expanded features and anticipate evolving stakeholder expectations and impacts.
Key Takeaways
- FDA launched a centralized, real-time adverse event monitoring system that will eventually unify all FDA adverse event databases with AI-enabled, near real-time data and enhanced analytics.
- At launch, AEMS includes data for drugs, biologics, cosmetics, and vaccines, with medical devices and remaining product areas scheduled for integration by the end of May 2026.
- If the AEMS functions for drugs and biologics signal the functionality for devices, AEMS will provide greater data access and usability: expanded historical data, visualization tools, and cross-product comparisons make analysis easier for external users.
- Easier data access may drive more stakeholder scrutiny and potential misinterpretation, requiring proactive monitoring by companies.
Background
The FDA historically operated multiple disparate adverse event monitoring systems for its various regulated product areas, each based on different software platforms. These systems were widely considered inefficient, costly to maintain, and difficult to navigate, leading to longstanding calls for modernization and consolidation.
In response, FDA has developed AEMS as a single, centralized platform for adverse event reports, consumer complaints, regulatory misconduct reports, and whistleblower submissions across all FDA centers. At launch, AEMS includes data for drugs, biologics, cosmetics, and vaccines, with medical devices and remaining product areas scheduled for integration by the end of May 2026.
When compared to the legacy databases, AEMS is designed to “strengthen safety surveillance capabilities through advanced case processing workflows, AI-based redaction and digitization tools, enhanced analytics, and comprehensive cross-product surveillance.”
Expanding on a 2025 announcement relating to drugs and biologics, data entry in AEMS will be in “near real-time” rather than much slower historic updates to FDA’s legacy databases (e.g., quarterly updates for the legacy drugs and biologics database, FAERS). Per FDA’s announcement, these faster update rates will be aided by AI technologies.
AEMS Enhances the Public’s Access to Adverse Event Information
If the current functions for drugs and biologics serve as an indicator of potential features for other FDA regulated product areas, AEMS will represent broader changes in available information for some of these product areas. For example, with respect to medical devices:
- AEMS provides access to adverse events dating back to 1986 (MAUDE only includes data from the last decade)
- AEMS allows users the ability to sort and visualize data by automatically generating graphical representations of the selected fields (MAUDE offers no sort/visualization features)
The new platform’s incorporation of AI technologies to speed and aid in data processing and disclosure, coupled with visualization and cross-product comparison tools, substantially lowers the barrier for outside parties to search, analyze, and question adverse event patterns.
Implications and Recommendations
The introduction of AEMS represents a significant shift in the accessibility and transparency of FDA adverse event data, with several practical implications for companies and industry stakeholders:
- Increased Public and Legal Scrutiny: The enhanced searchability and ability to generate comparative data and visualizations may encourage consumers, advocacy groups, and plaintiffs’ lawyers to conduct their own analyses and raise new questions with manufacturers.
- Real-Time Data Monitoring: With data entered in near real-time, trends and safety signals may be identified and publicized more quickly than under prior systems, potentially accelerating media, legal, or regulatory responses. Further, the information disclosed in the resulting database may be impacted by FDA’s use of new and different methodologies to transform individually submitted reports into database entries.
While the system warns users about the limitations of the data (e.g., it may be inaccurate and include unverified claims), there is an increased risk that external parties may misinterpret or take data out of context when conducting their own reviews. Companies should consider proactively familiarizing themselves with AEMS’s features and monitoring how their products are represented in the new database. Internal stakeholder education regarding the data’s limitations and context may also help mitigate reputational or legal risks associated with potential misinterpretation of adverse event trends. Organizations may want to prepare for an uptick in inquiries from external parties who can now more easily access and analyze comprehensive adverse event data.
Conclusion
The FDA’s launch of AEMS marks an important evolution in safety data transparency and accessibility, offering single-platform advanced analytics and real-time information for drugs, biologics, cosmetics, and vaccines, with medical device data to be added in the near future. While current reporting obligations remain unchanged, the ease of data access and visualization may prompt increased scrutiny from various stakeholders. Companies should stay engaged with the rollout, understand the system’s capabilities, and anticipate new forms of external analysis and inquiry.